

Sec. 36, N¹/₂ and SE¹/₄.

The areas described aggregate 3,745 acres, more or less in San Bernardino County.

The purpose of the proposed withdrawal is to protect and preserved the status quo of the lands pending action on an application for withdrawal for military purposes under the Engle Act. Currently, the lands are not being used for military training purposes.

The use of a right-of-way or cooperative agreement would not prohibit new mineral location.

The proposed withdrawal would not require water.

There are no suitable alternative sites. The USMC analyzed lands elsewhere in the United States and concluded that the lands located adjacent to MCAGCC were the best site for the proposed training.

On or before December 13, 2010, all persons who wish to submit comments, suggestions, or objections in connection with the proposed withdrawal may present their views in writing to the BLM, Barstow Field Office Manager at the address indicated above.

Comments, including names and street addresses of respondents, will be available for public review at the BLM Barstow Field Office at the address above during regular business hours. Individual respondents may request confidentiality. Before including your address, phone number, e-mail address, or other personal identifying information in your comment, be advised that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold from public review your personal identifying information, we cannot guarantee that we will be able to do so.

Notice is hereby given that a public meeting will be afforded in connection with the proposed withdrawal. A notice of the time and place of the public meeting will be published in the **Federal Register** and a local newspaper at least 30 days before the scheduled date of the meeting.

This withdrawal proposal will be processed in accordance with the regulations set forth in 43 CFR Part 2300.

For a period of 2 years from the date of publication of this notice in the **Federal Register**, the lands will be segregated from settlement, sale, location and entry under the public land laws, including the United States mining laws, and from the operation of the mineral and geothermal leasing laws and the Materials Act of 1947 unless the application is denied or canceled or the

withdrawal is approved prior to that date.

Licenses, permits, cooperative agreement, or discretionary land use authorizations of a temporary nature which will not significantly impact the values to be protected by the withdrawal may be allowed with the approval of the authorized officer of BLM during the segregative period.

Authority: 43 CFR 2310.3–1(a), (b)(1) and (2).

Karla D. Norris,

Associate Deputy State Director, CA–930.

[FR Doc. 2010–22817 Filed 9–13–10; 8:45 am]

BILLING CODE 3810–FF–P

INTERNATIONAL TRADE COMMISSION

[USITC SE–10–027]

Government in the Sunshine Act Meeting Notice

AGENCY HOLDING THE MEETING: United States International Trade Commission.

TIME AND DATE: September 20, 2010 at 1 p.m.

PLACE: Room 101, 500 E Street, SW., Washington, DC 20436, Telephone: (202) 205–2000.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:

1. Agenda for future meetings: none.
2. Minutes.
3. Ratification List.
4. Inv. No. 731–TA–125 (Third Review) (Potassium Permanganate from China)—briefing and vote. (The Commission is currently scheduled to transmit its determination and Commissioners' opinions to the Secretary of Commerce on or before September 30, 2010.)
5. Inv. Nos. 731–TA–1082 and 1083 (Review)(Chlorinated Isocyanurates from China and Spain)—briefing and vote. (The Commission is currently scheduled to transmit its determinations and Commissioners' opinions to the Secretary of Commerce on or before September 30, 2010.)
6. Outstanding action jackets: none.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.

Issued: September 10, 2010.

William R. Bishop,

Hearings and Meetings Coordinator.

[FR Doc. 2010–23055 Filed 9–10–10; 4:15 pm]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

[OMB Number 1103–0016]

Justice Management Division; Agency Information Collection Activities: Proposed Collection; Comments Requested

ACTION: 30-Day Notice of Information Collection Under Review: Certification of Identity.

The Department of Justice (DOJ), Justice Management Division, Facilities and Administrative Services Staff (JMD/FASS) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 75, Number 133 page 39972 on July 13, 2010, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until October 14, 2010. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to (202)–395–5806.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to

respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of This Information Collection

(1) *Type of Information Collection:* Extension of a Currently Approved Collection.

(2) *Title of the Form/Collection:* Certification of Identity.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form DOJ-361. Facilities and Administrative Services Staff, Justice Management Division, U.S. Department of Justice.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:* Primary: American Citizens. Other: Federal Government. The information collection will be used by the Department to identify individuals requesting certain records under the Privacy Act. Without this form an individual cannot obtain the information requested.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that 27,000 respondents will complete the form within approximately 30 minutes.

(6) *An estimate of the total burden (in hours) associated with the collection:* There are an estimated 13,500 annual burden hours associated with this collection.

If Additional Information is Required Contact: Lynn Murray, Department Clearance Officer, United States Department of Justice, Policy and Planning Staff, Justice Management Division, Suite 1600, Patrick Henry Building, 601 D Street, NW., Washington, DC 20530.

Dated: September 8, 2010.

Lynn Murray,

Department Clearance Officer, PRA, United States Department of Justice.

[FR Doc. 2010-22888 Filed 9-13-10; 8:45 am]

BILLING CODE 4410-CW-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-318F]

Controlled Substances: Final Revised Aggregate Production Quotas for 2010

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of final aggregate production quotas for 2010.

SUMMARY: This notice establishes final 2010 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA). DEA has taken into consideration comments received in response to a notice of the proposed revised aggregate production quotas for 2010 published June 23, 2010 (75 FR 35838).

DATES: *Effective Date:* September 14, 2010.

FOR FURTHER INFORMATION CONTACT:

Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant 28 CFR 0.104.

The 2010 aggregate production quotas represent those quantities of controlled substances in schedules I and II that may be produced in the United States in 2010 to provide adequate supplies of each substance for: The estimated medical, scientific, research and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks (21 U.S.C. 826(a) and 21 CFR 1303.11). These quotas do not include imports of controlled substances.

On June 23, 2010, a notice of the proposed revised 2010 aggregate production quotas for certain controlled substances in schedules I and II was published in the **Federal Register** (75 FR 35838). All interested persons were invited to comment on or object to these proposed aggregate production quotas on or before July 23, 2010.

Fourteen companies, thirteen DEA registered manufacturers and one non-registrant, commented on a total of 28 schedules I and II controlled substances within the published comment period. Comments received proposed that the aggregate production quotas for alfentanil, amphetamine (for conversion), amphetamine (for sale), codeine (for conversion), codeine (for sale), dextropropoxyphene, dihydromorphone, diphenoxylate, gamma hydroxybutyric acid, hydrocodone, hydromorphone,

lisdexamfetamine, meperidine, methadone, methylphenidate, morphine (for conversion), morphine (for sale), nabilone, opium (tincture), oxycodone (for conversion), oxycodone (for sale), oxymorphone (for sale), remifentanil, sufentanil, tapentadol, tetrahydrocannabinols, thebaine and tilidine were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks.

DEA has taken into consideration the above comments along with the relevant 2009 year-end inventories, initial 2010 manufacturing quotas, 2010 export requirements, actual and projected 2010 sales, research, product development requirements and additional applications received. Based on this information, the DEA has adjusted the final 2010 aggregate production quotas for alfentanil, amphetamine (for conversion), amphetamine (for sale), carfentanil, dihydromorphone, diphenoxylate, marijuana, morphine (for sale), noroxymorphone (for sale), opium (tincture), oxycodone (for conversion), oxycodone (for sale), oxymorphone (for conversion), oxymorphone (for sale), tapentadol, tetrahydrocannabinols, and tilidine.

4-anilino-N-phenethyl-4-piperidine (ANPP) pursuant to DEA's final rule published in the **Federal Register** on June 29, 2010 (75 FR 37295) will be controlled as a schedule II controlled substance on August 30, 2010. As such, DEA has established an aggregate production quota for ANPP to meet the estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks.

Regarding codeine (for conversion), codeine (for sale), dextropropoxyphene, gamma hydroxybutyric acid, hydrocodone, hydromorphone, lisdexamfetamine, meperidine, methadone, methylphenidate, morphine (for conversion), nabilone, remifentanil, sufentanil, and thebaine, DEA has determined that the proposed revised 2010 aggregate production quotas are sufficient to meet the current 2010 estimated medical, scientific, research, and industrial needs of the United States and to provide for adequate inventories.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA (21 U.S.C. 826), and delegated to the Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy Administrator, pursuant to 28 CFR 0.104, the Deputy